002022 Shanghai Kehua Bio-engineering
WatchlistShanghai Kehua Bio-engineering News
Kehua Biotech (002022) 2020 Semi-Annual Report Review: Molecular Diagnostics Business Is Growing Rapidly, POLARIS Series Products Are Worth Looking Forward To
Kehua Biotech (002022): Kehua Biotech's regular business is expected to resume growth after being pressured by the pandemic in the short term
Kehua Biotech (002022): The largest shareholder changed hands and entered a new stage in the development of the company
Comment on Kehua Biology (002022) Annual report in 2019 and Quarterly report in 2020: new products with rapid growth in molecular diagnostic business are worth looking forward to.
Kehua Biotech (002022) Interim Review: Performance Meets Expectations “Product+Channel” Accelerates Deployment
Kehua Biotech (002022) Interim Report Review: Channel Business Expansion Drives Steady Growth in Performance
Kehua Biotech (002022) review: epitaxial mergers and acquisitions continue to improve the molecular diagnosis layout
Kehua Biotech (002022) Quarterly Report Review: Revenue Growth Rate Is Fast, Endogeny+Epitaxial Development Simultaneous
Kehua Biotech (002022) Quarterly Report Review: Channel Integration Actively Promotes Performance Growth Is Expected to Recover
Kehua Biotech (002022) Annual Report Review: Performance is gradually improving the overall layout of products+channels
Kehua Biotech (002022) Annual Report Review: Performance is gradually improving, integrating channels, strengthening exploration of new business models
Kehua Biotech (002022) Annual Report Review: Product Improvement+Channel Integration Performance Growth Is Worth Looking forward to
Kehua Biotech (002022) Review: Equity Incentives Announced Performance Growth Expected
Kehua Biotech (002022) Review: Fourth quarter results resumed month-on-month, equity incentives introduced
Kehua Biotech (002022) Dynamic Tracking: Performance Meets Expectations, “Product+Channel” Grows Together
Kehua Biotech (002022) Dynamic Tracking: “Joining Aohua+Hitachi Cooperation” Will Strengthen Existing Product Lines
Kehua Biotech (002022) Third Quarterly Report Review: Guizhou's bid execution affects current profit and is expected to contribute to future performance
Kehua Biotech (002022) Third Quarterly Report Review: Strengthening Channel Construction and Continuing to Promote the “Endogenous Growth+Epitaxial Expansion” Strategy
Kehua Biotech (002022) Quarterly Review: Channel Integration Optimization Performance Can Be Expected at an inflection point
Kehua Biotech (002022) Interim Report: The pace of channel mergers and acquisitions has synergistic effects with existing business